Biomm S.A. (BVMF:BIOM3)

Brazil · Delayed Price · Currency is BRL

6.44

-0.33 (-4.87%)

Aug 26, 2026, 5:03 PM GMT-3

Market Cap	926.49M -2.6%
Revenue (ttm)	384.42M +176.5%
Net Income	30.33M
EPS	0.22
Shares Out	136.85M
PE Ratio	30.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,700
Open	6.63
Previous Close	6.77
Day's Range	6.44 - 6.63
52-Week Range	4.82 - 10.39
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tu... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 130

Stock Exchange Brazil Stock Exchange

Ticker Symbol BIOM3

Full Company Profile

Financial Performance

In 2025, Biomm's revenue was 269.30 million, an increase of 88.45% compared to the previous year's 142.91 million. Losses were -6.69 million, -91.34% less than in 2024.

Financial Statements